Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Allergan plc    AGN   IE00BY9D5467

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets

Allergan says revenue from aesthetics unit may double by 2025

share with twitter share with LinkedIn share with facebook
share via e-mail
09/14/2018 | 07:49pm CEST
The Allergan logo is seen in this photo illustration

NEW YORK (Reuters) - Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

The drugmaker announced earlier on Friday the acquisition of Bonti Inc, which makes a shorter-acting neurotoxin than Botox.

Allergan is also doubling its investment in direct-to-consumer ad spending and beefing up its sales force as companies like Revance Therapeutics Inc and Evolus Inc vie to wrest market share with rival treatments to Botox. The company made the announcements at its Medical Aesthetics Day in New York.

Chief Commercial Officer Bill Meury said Allergan expects revenue at its medical aesthetics unit to grow to $7 billion to $8 billion. That compares with revenue of $3.8 billion from the business in 2017.

Beyond Botox, the unit includes dermal filler Juvederm, the CoolSculpting fat-freezing systems, and other treatments.

He said the forecast implied an 8 to 10 percent compound annual growth rate.

Meury said the Bonti acquisition would allow the company to market a new "starter toxin." Patients could test drive the treatment, which lasts for two to four weeks, to help them decide if they want to use longer-term Botox.

Shares of Allergan fell 0.9 percent to $188.21 on Friday, while shares of Revance were down 1.1 percent and Evolus fell around 2.5 percent.

(The story corrects Allergan company stock price in final paragraph.)

(Reporting by Michael Erman; Editing by Chizu Nomiyama and Bernadette Baum)

By Michael Erman

Stocks mentioned in the article
ChangeLast1st jan.
ALLERGAN PLC -0.20% 187.6 Delayed Quote.16.95%
EVOLUS INC -0.66% 17.94 Delayed Quote.0.00%
REVANCE THERAPEUTICS INC 2.57% 25.95 Delayed Quote.-29.79%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ALLERGAN PLC
09/20ALLERGAN : to Acquire Bonti Adding New Neurotoxin Programs to Medical Aesthetics..
09/20ALLERGAN : Unveils Spotlyte™, A First-In-Category Digital Hub Designed To ..
09/20ALLERGAN : to Host Medical Aesthetics Day Event on September 14, 2018
09/20ALLERGAN : Study Results from Allergan Update Understanding of Acute Kidney Inju..
09/20ALLERGAN : Teams Up with Actor Scott Eastwood to Encourage Recognition of World ..
09/20ALLERGAN : Announces Results of Higher Dose BOTOX Cosmetic (onabotulinumtoxinA) ..
09/19ALLERGAN : Announces Plans to Build First Medical Aesthetics Innovation Center i..
09/19ALLERGAN : Announces Results of Higher Dose BOTOX Cosmetic for the Treatment of ..
09/19ALLERGAN : Highlights Key Growth Drivers for Medical Aesthetics
09/19SOSEI : Allergan to delay trials of dementia candidate
More news
News from SeekingAlpha
09/25Pfizer facing difficult path to ramp up biosimilar business 
09/24Express Scripts taking credit for Gilead's planned launch of generic HCV meds 
09/18Allergan Snaps Up Early Stage Startup, Goes Back To Its Aesthetic Roots 
09/18YOUR DAILY PHARMA SCOOP : Alnylam Regains, Karyopharm Positive, Teva Approved 
09/18Senate passes opioid crisis bill 
Financials ($)
Sales 2018 15 523 M
EBIT 2018 7 411 M
Net income 2018 -1 186 M
Debt 2018 23 063 M
Yield 2018 1,47%
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 5,59x
EV / Sales 2019 5,35x
Capitalization 63 680 M
Duration : Period :
Allergan plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALLERGAN PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 212 $
Spread / Average Target 13%
EPS Revisions
Brenton L. Saunders Chairman, President & Chief Executive Officer
Wayne R. Swanton Executive Vice President-Global Operations
Matthew M. Walsh Chief Financial Officer & Executive Vice President
C. David Nicholson Chief Research & Development Officer
Charles Hugh-Jones Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ALLERGAN PLC16.95%63 680
JOHNSON & JOHNSON2.26%376 847
PFIZER20.90%257 522
NOVARTIS-0.63%217 697
ROCHE HOLDING LTD.-5.48%209 212
MERCK AND COMPANY25.79%188 241